modelLefamulin

Diagram of Lefamulin

Extends from Pharmacolibrary.Drugs.ATC.J.J01XX12.

Information

name:Lefamulin
ATC code:J01XX12
route:intravenous
compartments:2
dosage:150mg
volume of distribution:34.2L
clearance:11.9L/h
other parameters in model implementation

Lefamulin is a pleuromutilin class antibiotic indicated for the treatment of community-acquired bacterial pneumonia (CABP) in adults. It is approved and used clinically and possesses activity against a range of Gram-positive and atypical bacterial pathogens.

Pharmacokinetics

Pharmacokinetics in healthy adult subjects following intravenous administration.

References

  1. Zhang, L, et al., & Rubino, CM (2019). Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods. The Journal of antimicrobial chemotherapy 74(Suppl 3) iii27–iii34. DOI:10.1093/jac/dkz088 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30949708

  2. van Os, W, & Zeitlinger, M (2024). Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. The Journal of antimicrobial chemotherapy 79(2) 443–446. DOI:10.1093/jac/dkad401 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38174805

  3. Bian, X, et al., & Zhang, J (2024). Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia. Frontiers in pharmacology 15 1456741–None. DOI:10.3389/fphar.2024.1456741 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39525637

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)